Introduction: Risk-reducing-salpingo-oophorectomy (RRSO) inevitably leads BRCA mutation carriers to premature menopause. Areas covered: To evaluate the existing evidence for use of postmenopausal hormone therapy (HT) in BRCAmc, after RRSO or menopause occurring naturally, for both breast cancer (BC) survivors and those without BC. Expert opinion: All BC survivors are excluded from any HT treatment: in other BRCAmc, before 51 years of age the benefits of HT overcome the risks after RRSO and/or premature ovarian insufficiency (POF). After 51 years of age, it is important to treat only women with important vasomotor symptoms, after the failure of alternative therapies. Estrogens-only therapy plays a key role in hysterectomized women (HW). In the case of an intact uterus (UW), associations with the lowest dose of progestins/natural progesterone derivatives have to be preferred, as progestins has been shown to play an important role in BC transformation, especially in BRCA1mc. No studies have been performed in BRCAmc with regard to ‘progestin-free’ HT, in particular the old tibolone (both in HW and UW) and the new tissue-selective estrogen complex (in UW). However, preliminary data obtained from the general population are reassuring about the use of these ‘progestin-free’ preparations and BC safety.

Postmenopausal hormone therapy in BRCA gene mutation carriers: to whom and which? / Grandi, G.; Caroli, M.; Cortesi, L.; Toss, A.; Tazzioli, G.; Facchinetti, F.. - In: EXPERT OPINION ON DRUG SAFETY. - ISSN 1474-0338. - 19:8(2020), pp. 1025-1030. [10.1080/14740338.2020.1791818]

Postmenopausal hormone therapy in BRCA gene mutation carriers: to whom and which?

Grandi G.
;
Caroli M.;Cortesi L.;Toss A.;Tazzioli G.;Facchinetti F.
2020

Abstract

Introduction: Risk-reducing-salpingo-oophorectomy (RRSO) inevitably leads BRCA mutation carriers to premature menopause. Areas covered: To evaluate the existing evidence for use of postmenopausal hormone therapy (HT) in BRCAmc, after RRSO or menopause occurring naturally, for both breast cancer (BC) survivors and those without BC. Expert opinion: All BC survivors are excluded from any HT treatment: in other BRCAmc, before 51 years of age the benefits of HT overcome the risks after RRSO and/or premature ovarian insufficiency (POF). After 51 years of age, it is important to treat only women with important vasomotor symptoms, after the failure of alternative therapies. Estrogens-only therapy plays a key role in hysterectomized women (HW). In the case of an intact uterus (UW), associations with the lowest dose of progestins/natural progesterone derivatives have to be preferred, as progestins has been shown to play an important role in BC transformation, especially in BRCA1mc. No studies have been performed in BRCAmc with regard to ‘progestin-free’ HT, in particular the old tibolone (both in HW and UW) and the new tissue-selective estrogen complex (in UW). However, preliminary data obtained from the general population are reassuring about the use of these ‘progestin-free’ preparations and BC safety.
2020
10-lug-2020
19
8
1025
1030
Postmenopausal hormone therapy in BRCA gene mutation carriers: to whom and which? / Grandi, G.; Caroli, M.; Cortesi, L.; Toss, A.; Tazzioli, G.; Facchinetti, F.. - In: EXPERT OPINION ON DRUG SAFETY. - ISSN 1474-0338. - 19:8(2020), pp. 1025-1030. [10.1080/14740338.2020.1791818]
Grandi, G.; Caroli, M.; Cortesi, L.; Toss, A.; Tazzioli, G.; Facchinetti, F.
File in questo prodotto:
File Dimensione Formato  
Postmenopausal.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 1.34 MB
Formato Adobe PDF
1.34 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1208169
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 7
social impact